{
    "clinical_study": {
        "@rank": "144746", 
        "arm_group": {
            "arm_group_label": "isoniazid rechalleng", 
            "arm_group_type": "Experimental", 
            "description": "When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly."
        }, 
        "brief_summary": {
            "textblock": "To improve the treatment outcome in patients with tuberculosis and integrate the\n      pharmacogenetics into clinical practice, the information of NAT2 genotyping was used in\n      re-challenge protocol for isoniazid (INH) titration in patients with anti-tuberculosis\n      medication-induced hepatitis."
        }, 
        "brief_title": "NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatotoxicity", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. >= 18 years.\n\n          2. Take INH for at least a week.\n\n          3. abnormal liver function (ALT (alanine, transaminase) increased by more than three\n             times the upper limit of normal, or ALT higher than twice the upper limit of normal\n             and total bilirubin higher than 2.0 mg / dL\n\n        Exclusion Criteria:\n\n        1.Taking INH before liver function abnormalities. 2."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076685", 
            "org_study_id": "200805015M"
        }, 
        "intervention": {
            "arm_group_label": "isoniazid rechalleng", 
            "description": "dose adjustment according to the pharmacogenomic results", 
            "intervention_name": "isoniazid", 
            "intervention_type": "Drug", 
            "other_name": "Duracin, Rifina"
        }, 
        "intervention_browse": {
            "mesh_term": "Isoniazid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pharmacogenetics", 
            "anti-tuberculosis drug", 
            "genetic polymorphism", 
            "isoniazid"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "ljshen@ntu.edu.tw", 
                "last_name": "Li-Jiuan Shen, Ph.D."
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan"
                }, 
                "name": "National Taiwan University Hospital"
            }, 
            "investigator": {
                "last_name": "Li-Jiuan Shen, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis", 
        "overall_contact": {
            "email": "ljshen@ntu.edu.tw", 
            "last_name": "Li-Jiuan Shen, Ph.D."
        }, 
        "overall_official": {
            "affiliation": "Nationa Taiwan University Hospital", 
            "last_name": "Shen Li Jiuan, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In this study, we would like to test the hypothesis of NAT2 genotyping helping in isoniazid rechallenge after patients experienced adverse effects of anti-TB treatment. Therefore, to observe the patients can re-use isoniazid successfully is an important outcome measure in this study.", 
            "measure": "successful re-use of isoniazid for TB treatment", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076685"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2007", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}